Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Discovery of a glucocorticoid receptor (GR) activity signature using selective GR antagonism in ER-negative breast cancer.

West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, Greene GL, Boughey JC, Goetz MP, Kalari KR, Wang L, Fleming GF, Győrffy B, Conzen SD.

Clin Cancer Res. 2018 Apr 10. pii: clincanres.2793.2017. doi: 10.1158/1078-0432.CCR-17-2793. [Epub ahead of print]

PMID:
29636357
2.

Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.

Martínez-Canales S, López de Rodas M, Nuncia-Cantarero M, Páez R, Amir E, Győrffy B, Pandiella A, Galán-Moya EM, Ocaña A.

Cancer Med. 2018 Mar 25. doi: 10.1002/cam4.1406. [Epub ahead of print]

3.

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.

Győrffy B, Pongor L, Bottai G, Li X, Budczies J, Szabó A, Hatzis C, Pusztai L, Santarpia L.

Br J Cancer. 2018 Apr;118(8):1107-1114. doi: 10.1038/s41416-018-0030-0. Epub 2018 Mar 21.

PMID:
29559730
4.

Inhibin is a novel paracrine factor for tumor angiogenesis and metastasis.

Singh P, Jenkins LM, Horst B, Alers V, Pradhan S, Kaur P, Srivastava T, Hempel N, Győrffy B, Broude EV, Lee NY, Mythreye K.

Cancer Res. 2018 Mar 13. pii: canres.2316.2017. doi: 10.1158/0008-5472.CAN-17-2316. [Epub ahead of print]

PMID:
29535220
5.

Transcriptome evolution from breast epithelial cells to basal-like tumors.

Santpere G, Alcaráz-Sanabria A, Corrales-Sánchez V, Pandiella A, Győrffy B, Ocaña A.

Oncotarget. 2017 Dec 8;9(1):453-463. doi: 10.18632/oncotarget.23065. eCollection 2018 Jan 2.

6.

[Colorectal cancer heterogeneity: the clinical impact of sporadic lesions arising via the serrated pathway].

Ágoston EI, Horváth E, Győrffy B, Harsányi L, Szász AM.

Orv Hetil. 2018 Feb;159(6):206-214. doi: 10.1556/650.2018.30974. Review. Hungarian.

PMID:
29400100
7.

Erratum to "Effect of extended oral contraception use on the prevalence of fetal trisomy 21 in women aged at least 35 years": [Int J Gynecol Obstet 138(2017) 261-266].

Horányi D, Babay LÉ, Rigó J Jr., Győrffy B, Nagy GR.

Int J Gynaecol Obstet. 2018 Feb;140(2):258. doi: 10.1002/ijgo.12400. No abstract available.

PMID:
29313983
8.

A snapshot of 3649 Web-based services published between 1994 and 2017 shows a decrease in availability after 2 years.

Osz Á, Pongor LS, Szirmai D, Gyorffy B.

Brief Bioinform. 2017 Dec 8. doi: 10.1093/bib/bbx159. [Epub ahead of print]

PMID:
29228189
9.

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.

Budczies J, Denkert C, Győrffy B, Schirmacher P, Stenzinger A.

BMC Med Genomics. 2017 Dec 6;10(1):74. doi: 10.1186/s12920-017-0308-8.

10.

CEACAM6 is a prognostic biomarker and potential therapeutic target for gastric carcinoma.

Ru GQ, Han Y, Wang W, Chen Y, Wang HJ, Xu WJ, Ma J, Ye M, Chen X, He XL, Győrffy B, Zhao ZS, Huang D.

Oncotarget. 2017 Jul 20;8(48):83673-83683. doi: 10.18632/oncotarget.19415. eCollection 2017 Oct 13.

11.

UCP2 and PRMT1 are key prognostic markers for lung carcinoma patients.

Madreiter-Sokolowski CT, Győrffy B, Klec C, Sokolowski AA, Rost R, Waldeck-Weiermair M, Malli R, Graier WF.

Oncotarget. 2017 Aug 28;8(46):80278-80285. doi: 10.18632/oncotarget.20571. eCollection 2017 Oct 6.

12.

DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer.

Menyhart O, Budczies J, Munkácsy G, Esteva FJ, Szabó A, Miquel TP, Győrffy B.

Oncotarget. 2017 Aug 24;8(44):77207-77218. doi: 10.18632/oncotarget.20430. eCollection 2017 Sep 29.

13.

Quantitative proteomics identifies STEAP4 as a critical regulator of mitochondrial dysfunction linking inflammation and colon cancer.

Xue X, Bredell BX, Anderson ER, Martin A, Mays C, Nagao-Kitamoto H, Huang S, Győrffy B, Greenson JK, Hardiman K, Spence JR, Kamada N, Shah YM.

Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9608-E9617. doi: 10.1073/pnas.1712946114. Epub 2017 Oct 23.

PMID:
29078383
14.

PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer.

Xu H, Han Y, Lou J, Zhang H, Zhao Y, Győrffy B, Li R.

Oncotarget. 2017 May 13;8(41):69520-69526. doi: 10.18632/oncotarget.17846. eCollection 2017 Sep 19.

15.

Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles.

Cortés M, Sanchez-Moral L, de Barrios O, Fernández-Aceñero MJ, Martínez-Campanario MC, Esteve-Codina A, Darling DS, Győrffy B, Lawrence T, Dean DC, Postigo A.

EMBO J. 2017 Nov 15;36(22):3336-3355. doi: 10.15252/embj.201797345. Epub 2017 Oct 16.

PMID:
29038174
16.

Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.

Stires H, Heckler MM, Fu X, Li Z, Grasso CS, Quist MJ, Lewis JA, Klimach U, Zwart A, Mahajan A, Győrffy B, Cavalli LR, Riggins RB.

Mol Cell Endocrinol. 2017 Sep 19. pii: S0303-7207(17)30509-9. doi: 10.1016/j.mce.2017.09.024. [Epub ahead of print]

17.

Alterations in SCAI Expression during Cell Plasticity, Fibrosis and Cancer.

Gasparics Á, Kökény G, Fintha A, Bencs R, Mózes MM, Ágoston EI, Buday A, Ivics Z, Hamar P, Győrffy B, Rosivall L, Sebe A.

Pathol Oncol Res. 2017 Aug 16. doi: 10.1007/s12253-017-0293-4. [Epub ahead of print]

PMID:
28815470
18.

linc00673 (ERRLR01) is a prognostic indicator of overall survival in breast cancer.

Abdul-Rahman U, Győrffy B, Adams BD.

Transcription. 2018;9(1):17-29. doi: 10.1080/21541264.2017.1329684. Epub 2017 Oct 4.

PMID:
28795861
19.

Cell Dispersal Influences Tumor Heterogeneity and Introduces a Bias in NGS Data Interpretation.

Pongor L, Harami-Papp H, Méhes E, Czirók A, Győrffy B.

Sci Rep. 2017 Aug 4;7(1):7358. doi: 10.1038/s41598-017-07487-z.

20.

Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.

Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, Győrffy B, Brastianos PK, Binder DC, Sosman JA, Giles FJ, James CD, Horbinski C, Stupp R, Wainwright DA.

Clin Cancer Res. 2017 Nov 1;23(21):6650-6660. doi: 10.1158/1078-0432.CCR-17-0120. Epub 2017 Jul 27.

PMID:
28751450
21.

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients.

Bottai G, Raschioni C, Székely B, Di Tommaso L, Szász AM, Losurdo A, Győrffy B, Ács B, Torrisi R, Karachaliou N, Tőkés T, Caruso M, Kulka J, Roncalli M, Santoro A, Mantovani A, Rosell R, Reis-Filho JS, Santarpia L.

NPJ Breast Cancer. 2016 Nov 2;2:16033. doi: 10.1038/npjbcancer.2016.33. eCollection 2016.

22.

ADIPOQ/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11/LKB1-mediated activation of the AMPK-ULK1 axis.

Chung SJ, Nagaraju GP, Nagalingam A, Muniraj N, Kuppusamy P, Walker A, Woo J, Győrffy B, Gabrielson E, Saxena NK, Sharma D.

Autophagy. 2017 Aug 3;13(8):1386-1403. doi: 10.1080/15548627.2017.1332565. Epub 2017 Jul 11.

PMID:
28696138
23.

Effect of extended oral contraception use on the prevalence of fetal trisomy 21 in women aged at least 35 years.

Horányi D, Babay LÉ, Rigó J Jr, Győrffy B, Nagy GR.

Int J Gynaecol Obstet. 2017 Sep;138(3):261-266. doi: 10.1002/ijgo.12238. Epub 2017 Jul 5. Erratum in: Int J Gynaecol Obstet. 2018 Feb;140(2):258.

PMID:
28608970
24.

Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3.

Sengupta S, Nagalingam A, Muniraj N, Bonner MY, Mistriotis P, Afthinos A, Kuppusamy P, Lanoue D, Cho S, Korangath P, Shriver M, Begum A, Merino VF, Huang CY, Arbiser JL, Matsui W, Győrffy B, Konstantopoulos K, Sukumar S, Marignani PA, Saxena NK, Sharma D.

Oncogene. 2017 Oct 12;36(41):5709-5721. doi: 10.1038/onc.2017.164. Epub 2017 Jun 5.

25.

Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors.

Martínez-Canales S, Cifuentes F, López De Rodas Gregorio M, Serrano-Oviedo L, Galán-Moya EM, Amir E, Pandiella A, Győrffy B, Ocaña A.

PLoS One. 2017 May 4;12(5):e0175128. doi: 10.1371/journal.pone.0175128. eCollection 2017.

26.

Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer.

Safonov A, Jiang T, Bianchini G, Győrffy B, Karn T, Hatzis C, Pusztai L.

Cancer Res. 2017 Jun 15;77(12):3317-3324. doi: 10.1158/0008-5472.CAN-16-3478. Epub 2017 Apr 20.

PMID:
28428277
27.

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors.

Pérez-Peña J, Alcaraz-Sanabria A, Nieto-Jiménez C, Páez R, Corrales-Sánchez V, Serrano-Oviedo L, Wali VB, Patwardhan GA, Amir E, Győrffy B, Pandiella A, Ocaña A.

Oncotarget. 2017 Mar 28;8(13):21733-21740. doi: 10.18632/oncotarget.15562.

28.

Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.

Iwamoto T, Katagiri T, Niikura N, Miyoshi Y, Kochi M, Nogami T, Shien T, Motoki T, Taira N, Omori M, Tokuda Y, Fujiwara T, Doihara H, Gyorffy B, Matsuoka J.

Oncotarget. 2017 Apr 18;8(16):26122-26128. doi: 10.18632/oncotarget.15385.

29.

Reproducibility and Prognostic Potential of Ki-67 Proliferation Index when Comparing Digital-Image Analysis with Standard Semi-Quantitative Evaluation in Breast Cancer.

Ács B, Madaras L, Kovács KA, Micsik T, Tőkés AM, Győrffy B, Kulka J, Szász AM.

Pathol Oncol Res. 2018 Jan;24(1):115-127. doi: 10.1007/s12253-017-0220-8. Epub 2017 Apr 11.

PMID:
28401450
30.

The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone.

Bellanger A, Donini CF, Vendrell JA, Lavaud J, Machuca-Gayet I, Ruel M, Vollaire J, Grisard E, Győrffy B, Bièche I, Peyruchaud O, Coll JL, Treilleux I, Maguer-Satta V, Josserand V, Cohen PA.

J Pathol. 2017 May;242(1):73-89. doi: 10.1002/path.4882. Epub 2017 Mar 27.

PMID:
28207159
31.

Comparison of 5 Ki-67 antibodies regarding reproducibility and capacity to predict prognosis in breast cancer: does the antibody matter?

Ács B, Kulka J, Kovács KA, Teleki I, Tőkés AM, Meczker Á, Győrffy B, Madaras L, Krenács T, Szász AM.

Hum Pathol. 2017 Jul;65:31-40. doi: 10.1016/j.humpath.2017.01.011. Epub 2017 Feb 8.

PMID:
28188752
32.

Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.

McDermott MS, Chumanevich AA, Lim CU, Liang J, Chen M, Altilia S, Oliver D, Rae JM, Shtutman M, Kiaris H, Győrffy B, Roninson IB, Broude EV.

Oncotarget. 2017 Feb 21;8(8):12558-12575. doi: 10.18632/oncotarget.14894.

33.

Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.

Sávolt Á, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, Győrffy B, Kásler M, Mátrai Z.

Eur J Surg Oncol. 2017 Apr;43(4):672-679. doi: 10.1016/j.ejso.2016.12.011. Epub 2017 Jan 16.

PMID:
28139362
34.

Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer.

Bottai G, Diao L, Baggerly KA, Paladini L, Győrffy B, Raschioni C, Pusztai L, Calin GA, Santarpia L.

Int J Mol Sci. 2017 Jan 19;18(1). pii: E194. doi: 10.3390/ijms18010194.

35.

The short- and long-term proteomic effects of sleep deprivation on the cortical and thalamic synapses.

Simor A, Györffy BA, Gulyássy P, Völgyi K, Tóth V, Todorov MI, Kis V, Borhegyi Z, Szabó Z, Janáky T, Drahos L, Juhász G, Kékesi KA.

Mol Cell Neurosci. 2017 Mar;79:64-80. doi: 10.1016/j.mcn.2017.01.002. Epub 2017 Jan 10.

PMID:
28087334
36.

Benzyl Isothiocyanate potentiates p53 signaling and antitumor effects against breast cancer through activation of p53-LKB1 and p73-LKB1 axes.

Xie B, Nagalingam A, Kuppusamy P, Muniraj N, Langford P, Győrffy B, Saxena NK, Sharma D.

Sci Rep. 2017 Jan 10;7:40070. doi: 10.1038/srep40070.

37.

HUWE1 is a critical colonic tumour suppressor gene that prevents MYC signalling, DNA damage accumulation and tumour initiation.

Myant KB, Cammareri P, Hodder MC, Wills J, Von Kriegsheim A, Győrffy B, Rashid M, Polo S, Maspero E, Vaughan L, Gurung B, Barry E, Malliri A, Camargo F, Adams DJ, Iavarone A, Lasorella A, Sansom OJ.

EMBO Mol Med. 2017 Feb;9(2):181-197. doi: 10.15252/emmm.201606684.

38.

ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1.

de Barrios O, Győrffy B, Fernández-Aceñero MJ, Sánchez-Tilló E, Sánchez-Moral L, Siles L, Esteve-Arenys A, Roué G, Casal JI, Darling DS, Castells A, Postigo A.

Gut. 2017 Apr;66(4):666-682. doi: 10.1136/gutjnl-2015-310838. Epub 2016 Dec 13.

PMID:
27965283
39.

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.

Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, Győrffy B, Lifton RP, Symmans WF, Pusztai L, Hatzis C.

PLoS Med. 2016 Dec 13;13(12):e1002193. doi: 10.1371/journal.pmed.1002193. eCollection 2016 Dec.

40.

[Internet-based opportunities in breast cancer diagnostics and research].

Nagy Á, Gyõrffy B.

Magy Onkol. 2016 Nov 29;60(4):273-280. Epub 2015 Dec 18. Hungarian.

41.

KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.

Nagy Á, Pongor LS, Szabó A, Santarpia M, Győrffy B.

Int J Cancer. 2017 Feb 15;140(4):930-937. doi: 10.1002/ijc.30509. Epub 2016 Nov 23.

42.
43.

Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer.

Patel H, Abduljabbar R, Lai CF, Periyasamy M, Harrod A, Gemma C, Steel JH, Patel N, Busonero C, Jerjees D, Remenyi J, Smith S, Gomm JJ, Magnani L, Győrffy B, Jones LJ, Fuller-Pace F, Shousha S, Buluwela L, Rakha EA, Ellis IO, Coombes RC, Ali S.

Clin Cancer Res. 2016 Dec 1;22(23):5929-5938. Epub 2016 Jun 14.

44.

miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.

Lánczky A, Nagy Á, Bottai G, Munkácsy G, Szabó A, Santarpia L, Győrffy B.

Breast Cancer Res Treat. 2016 Dec;160(3):439-446. doi: 10.1007/s10549-016-4013-7. Epub 2016 Oct 15.

PMID:
27744485
45.

Propagation on Molecular Interaction Networks: Prediction of Effective Drug Combinations and Biomarkers in Cancer Treatment.

Ligeti B, Menyhart O, Petric I, Gyorffy B, Pongor S.

Curr Pharm Des. 2017;23(1):5-28. doi: 10.2174/1381612822666161021162727. Review.

PMID:
27774896
46.

Guidelines for the selection of functional assays to evaluate the hallmarks of cancer.

Menyhárt O, Harami-Papp H, Sukumar S, Schäfer R, Magnani L, de Barrios O, Győrffy B.

Biochim Biophys Acta. 2016 Dec;1866(2):300-319. doi: 10.1016/j.bbcan.2016.10.002. Epub 2016 Oct 11. Review.

47.

Transcription Factor ZBP-89 Drives a Feedforward Loop of β-Catenin Expression in Colorectal Cancer.

Essien BE, Sundaresan S, Ocadiz-Ruiz R, Chavis A, Tsao AC, Tessier AJ, Hayes MM, Photenhauer A, Saqui-Salces M, Kang AJ, Shah YM, Győrffy B, Merchant JL.

Cancer Res. 2016 Dec 1;76(23):6877-6887. Epub 2016 Oct 10.

48.

LDB1 overexpression is a negative prognostic factor in colorectal cancer.

García SA, Swiersy A, Radhakrishnan P, Branchi V, Kanth Nanduri L, Győrffy B, Betzler AM, Bork U, Kahlert C, Reißfelder C, Rahbari NN, Weitz J, Schölch S.

Oncotarget. 2016 Dec 20;7(51):84258-84270. doi: 10.18632/oncotarget.12481.

49.

Validation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments.

Munkácsy G, Sztupinszki Z, Herman P, Bán B, Pénzváltó Z, Szarvas N, Győrffy B.

Mol Ther Nucleic Acids. 2016 Sep 27;5(9):e366. doi: 10.1038/mtna.2016.66.

50.

Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.

Kang MH, Jeong KJ, Kim WY, Lee HJ, Gong G, Suh N, Győrffy B, Kim S, Jeong SY, Mills GB, Park YY.

Oncogene. 2017 Mar 23;36(12):1745-1752. doi: 10.1038/onc.2016.327. Epub 2016 Sep 5.

PMID:
27593929

Supplemental Content

Loading ...
Support Center